Home > News > Sleep Disorders in Neuromuscular Diseases: Adaption in Care Provision During the COVID-19 Pandemic
COVID-19
Read Time: 7 mins

Sleep Disorders in Neuromuscular Diseases: Adaption in Care Provision During the COVID-19 Pandemic

Published Online: June 28th 2021 touchREVIEWS in Respiratory & Pulmonary Medicine. 2021;17(1):Online ahead of journal publication
Authors: Katherine E Cox-Flaherty, Eric J Gartman
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

Patients with neuromuscular disease frequently have comorbid sleep disorders. Hypoventilation, upper airway issues, central apnoeas and paroxysmal leg movements are all common in this patient population. It is imperative that these patients undergo a formal evaluation. However, the COVID-19 pandemic has presented many challenges that have necessitated adaptations in the provision of their care. Despite the hurdles created by infection control measures to completing evaluations, such as polysomnography and advanced pulmonary function testing, they generally can be accomplished in a safe manner. Care providers should exhibit caution to avoid the temptation to make clinical decisions based on substandard testing or prescribe suboptimal therapies in this population of patients. Finally, the challenges of the pandemic have also affected the availability of in-person clinical follow-up and assessment of treatment efficacy. The utility of telehealth in this manner has proven invaluable and has allowed for reliable high-quality care to be delivered to a potentially vulnerable population of patients.

Keywords

Sleep disorders, neuromuscular disease, COVID-19, pandemic, adaptations.

Article:

Sleep disturbances are exceedingly common and potentially morbid in patients with neuromuscular diseases (NMD).1 A constellation of physiologic changes occur in patients with NMDs which, in concert with normal physiologic changes during sleep, lead to decreased nocturnal ventilation that often precedes daytime hypoventilation. The standard manner in which we diagnose and treat sleep disorders in this patient population has become exceedingly challenging in the COVID-19 era. In this editorial, we aim to review healthcare delivery barriers that have been presented by the pandemic and how we can adapt our practice to maximize the care of NMD patients.

Physiology during sleep

A basic understanding of physiologic alterations during sleep in NMD patients is required to direct appropriate testing and treatment. A detailed review of the pathophysiology of sleep-disordered breathing in neuromuscular diseases has been described previously.2 While most clinicians recognize that patients with advanced NMD may develop issues with hypoventilation – at first, during sleep then, as their disease progresses, during wakefulness – it is important to appreciate that the spectrum of NMDs is highly variable and most patients do not develop clinically overt chronic ventilatory failure. NMDs span a wide range of conditions – from diaphragm disorders, congenital musculoskeletal abnormalities, relapsing/remitting neurologic conditions, to progressive neuromuscular disorders – and many are associated with sleep-disordered breathing that will go unnoticed if not formally evaluated. In addition to common sleep-disordered breathing issues, depending on the disease, NMD patients have additional physiologic alterations that lead to additional sleep abnormalities. For example, nocturnal hypoventilation occurs due to muscle atonia associated with rapid eye movement (REM), respiratory muscle weakness and, particularly, diaphragmatic weakness.2 Patients with bulbar muscle involvement may have additional airway issues during sleep. Central apnoea events are also common in this patient population for a variety of reasons depending upon the underlying pathology. Finally, paroxysmal limb movements are also common in several NMD conditions and should be screened for in these patients.3

Evaluation of sleep disorders in neuromuscular disease in the COVID-19 era

As stated above, patients with ‘neuromuscular disease’ are quite varied in their presentation and pathophysiology, and the workup (and subsequent treatment) of each patient needs to be individualized. For example, for patients with advanced progressive NMDs who clearly have chronic respiratory failure, empiric treatment with non-invasive ventilation is indicated and further testing likely is not needed. However, most patients do not always present with a known disorder or clear clinical picture, and a thorough evaluation is recommended (Table 1).

Infection control efforts due to the COVID-19 pandemic have varied widely and evolved over time, but suffice to say that they have hindered our ability to evaluate patients in the standard manner. Our first step in the evaluation remains straightforward, assuming access to care has been maintained. Through taking the patient’s history, we must ascertain the presence of morning headaches, daytime fatigue, generalized fatigue, excessive sleep time with nocturnal awakenings, snoring, witnessed apnoeas and shortness of breath with positional changes (due to changes in chest wall compliance). If there is any suspicion of an underlying sleep or ventilatory disorder, the evaluation should include checking for an elevated serum bicarbonate and elevated carbon dioxide level, which may be suggestive of chronic hypoventilation (though it may be absent without daytime hypoventilation).4

The next steps can include pulmonary function testing (PFT), specifically manoeuvres to evaluate respiratory muscle strength (e.g. maximal inspiratory pressure [MIP], maximal expiratory pressure [MEP] upright and supine spirometry); however, many pulmonary function laboratories remain prone to closure or have significant limitations on testing. Pre-testing for SARS-CoV-2 is often required, which can be an insurmountable barrier given the mobility constraints of many NMD patients and the excessive wait times for test results. Some PFT laboratories have decided not to require SARS-CoV-2 screening prior to testing, and instead have adapted their laboratories as full negative pressure rooms or outfitted the technicians in full protective gear for the duration of testing. Regardless of strategy, most PFT laboratories are operating at a reduced capacity due to infection control constraints.

Attended polysomnograms (PSG) including transcutaneous CO2 monitoring are the gold standard for assessment of sleep disturbances given their ability to create a comprehensive physiologic analysis of a patient’s sleep. This includes not only documenting obstructive and central events but also profiling subtle increases in PCO2 and decreases in O2 during REM sleep; patients with NMD are at increased risk for all of these. However, performing in-lab PSGs has become challenging during the COVID pandemic. Orchestrating full PSGs can be difficult in NMD patients with mobility issues at baseline, and currently with sleep laboratory closures and limitations it could prove impossible. Most laboratories that have reopened are requiring SARS-CoV-2 pre-testing, which presents similar challenges as described above.

Due to these issues, the concept of home testing becomes more appealing. However, it is important to remember that home studies are limited and only useful in patients with a high pre-test probability for uncomplicated moderate to severe obstructive sleep apnoea without additional sleep disorders.5 As such, home studies are not well suited for NMD patients as they are not designed to detect hypoventilation or central sleep apnoeas, and more advanced monitoring cannot be performed.5 In the current climate, a home study would only be appropriate if the physician suspects concomitant obstructive sleep apnoea, but would not be able to diagnose hypoventilation. Based upon symptoms or the severity of neuromuscular disease, it would be reasonable to start with nocturnal oximetry testing, which would detect severe nocturnal hypoventilation. If there is any suggestion of symptoms consistent with nocturnal hypoventilation, sleep-disordered breathing or potentially hypoventilation-driven oxygen desaturation on nocturnal oximetry, empiric treatment should be considered.

Treatment

The prescription for sleep-related ventilatory disorders in NMD patients is directed most effectively by the comprehensive physiologic profile provided by in-laboratory monitoring and titration. While some advanced NMD patients may be managed empirically with non-invasive ventilation, most NMD patients will not have overt chronic respiratory failure, and nocturnal assessment and treatment need to be tailored and adapted to an individual’s needs. This assessment allows for the evaluation of comorbid obstructive and central apnoeas, as well as the titration of expiratory airway pressures that will ensure airway patency and assure effective ventilation. Further, the formal interaction with trained respiratory therapists in this setting offers a unique opportunity for acclimation to the initiation of treatment.

Unfortunately, for the reasons stated above, such testing and personal interaction have become difficult to reliably obtain for many NMD patients. Depending on the clinical picture and the ability to obtain some elements of the evaluation, a provider may choose to implement therapy. Continuous positive airway pressure (CPAP) is generally not appropriate for use in patients with evidence of central apnoeas or hypoventilation, although some conditions may only affect the upper airway and CPAP would be indicated. For similar reasons, simple supplemental oxygen is not a sufficient therapy. Non-invasive positive pressure ventilation (NPPV) generally is the most appropriate therapy and can improve survival and quality of life.6–8 A bi-level device with a backup rate is the most commonly employed NPPV mode and can be used on an intermittent basis or eventually provide full ventilatory support. Newer modes of NPPV have been developed that theoretically improve upon the standard bi-level with a backup rate such as average volume-assured pressure support and intelligent volume-assured pressure support. While they have not demonstrated superiority with regard to functionality or survival in large studies over standard NPPV, mechanistically they are well suited to patients with NMD as they are designed to deliver a stable level of ventilation despite variation in respiratory efforts in different sleep stages.2 Medicare is currently covering positive airway pressure (PAP) devices based upon the clinician’s assessment of the patient without requiring a formal diagnosis with in-lab PSG or home sleep apnoea testing. Of note, it remains unclear what follow-up testing may be required after this is pandemic is over.

Given the empiric nature of this treatment strategy, frequent communication with the patient and remote interrogation of the device are suggested to ensure efficacy and safety. Home visits conducted by the respiratory therapists employed by the home care equipment supplier or specialized care teams (if available) can be invaluable in the current environment to assist in the initiation of and acclimation to NPPV, given the inconsistent availability of in-laboratory or in-person clinic assessments and follow-up. Titrating therapy remains challenging. Home transcutaneous capnometry (TcCO2) and ventilator-integrated end-tidal CO2 monitoring are options to estimate overnight PCO2 and ultimately ventilation. Both methods of home monitoring are valuable in that they may detect subtle transient episodes of hypoventilation not detected with intermittent blood gas assessment. It is notable that home TcCO2 monitoring remains expensive and somewhat impractical; however, in small studies, ventilator-integrated end-tidal CO2 monitoring seems to correlate well with both TcCO2 values and morning PCO2 values, and has the advantage of being relatively low cost.9 The existence of concomitant underlying parenchymal pulmonary disease would impact the accuracy of end tidal CO2 monitoring. The accuracy of both of these techniques is limited and should not completely replace blood gases. An additional challenge includes management of home PAP therapy in patients with potential COVID-19 infection given that NPPV is an aerosol-generating device and could, theoretically, disperse infective aerosols and spread to others. The risks remain unknown, and best clinical judgement should be applied. Theoretically, the use of non-vented masks with exhalation valves with viral filters and/or the use of closed-circuit ventilators could be employed to reduce transmission risk in these circumstances; however, it is unclear if these are reliably effective or would be logistically/financially feasible on a large scale. Further, despite these adaptations, significant uncertainty still exists, and even with these precautions in place maximum personal protective equipment should be employed (e.g. many hospitals currently place anyone on PAP therapy on aerosol precautions).

Access to care

The COVID pandemic has radically transformed clinical care delivery worldwide. In an effort to limit exposure to patients and medical staff, telemedicine has been widely adopted. It has the advantage of providing rapid and easy access to providers. Studies across several specialties suggest non-inferiority of virtual evaluations compared with in-person evaluations in terms of patient and caregiver satisfaction.10 The majority of NMDs progress slowly and are primarily managed on an outpatient basis, making them particularly appropriate for management via telemedicine.11 Additionally, patients with NMDs and respiratory failure often have challenges mobilizing personnel and equipment to attend clinic visits. Finally, there are fairly few providers who specialize in patients with NMDs and chronic respiratory failure, thus telemedicine may improve overall access to specialists. One randomized trial using telehealth in patients with amyotrophic lateral sclerosis demonstrated a reduced rate of hospitalizations.12 Long-term heavy reliance on telehealth has practical barriers to widespread implementation, including issues related to both commercial- and government-based insurance reimbursement and credentialing, as well as furthering inequities to patients without access to requisite electronic devices.13

Article Information:
Disclosure

Katherine E Cox-Flaherty and Eric J Gartman have no financial or non-financial relationships or activities to declare in relation to this article.

Review Process

Double-blind peer review.

Authorship

The named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.

Correspondence

Katherine E Cox-Flaherty, Division of Pulmonary, Critical Care, and Sleep Medicine, Rhode Island Hospital, 593 Eddy Street, POB Suite 224, Providence, RI 02903, USA.
E: katherine_cox@brown.edu

Support

No funding was received for the publication of this article.

Received

2020-09-29

References

  1. Guilleminault C, Shergill RP. Sleep-disordered breathing in neuromuscular disease. Curr Treat Options Neurol. 2002;4:107–12.
  2. Gartman E. Sleep disorders in neuromuscular diseases. US Respir Pulm Dis. 2018;3:27–32.
  3. Fereshtehnejad SM, Rahmani A, Shafieesabet M, et al. Prevalence and associated comorbidities of restless legs syndrome (RLS): Data from a large population-based door-to-door survey on 19176 adults in Tehran, Iran. PloS One.2017;12:e0172593.
  4. Bersanini C, Khirani S, Ramirez A, et al. Nocturnal hypoxaemia and hypercapnia in children with neuromuscular disorders. Eur Respir J. 2012;39:1206–12.
  5. Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13:479–504.
  6. Bourke SC, Tomlinson M, Williams TL, et al. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol. 2006;5:140–7.
  7. Bach JR, Martinez D. Duchenne muscular dystrophy: continuous noninvasive ventilatory support prolongs survival. Respir Care.2011;56:744–50.
  8. Berlowitz DJ, Howard ME, Fiore JF Jr, et al. Identifying who will benefit from non-invasive ventilation in amyotrophic lateral sclerosis/motor neurone disease in a clinical cohort. J Neurol Neurosurg Psychiatr.2016;87:280–6.
  9. Orlikowski D, Prigent H, Ambrosi X, et al. Comparison of ventilator-integrated end-tidal CO2 and transcutaneous CO2 monitoring in home-ventilated neuromuscular patients. Respir Med.2016;117:7–13.
  10. Hatcher-Martin JM, Adams JL, Anderson ER, et al. Telemedicine in neurology: Telemedicine Work Group of the American Academy of Neurology update. Neurology. 2020;94:30–8.
  11. Garibaldi M, Siciliano G, Antonini G. Telemedicine for neuromuscular disorders during the COVID-19 outbreak. J Neurol.2021;268:1–4.
  12. Hobson EV, Baird WO, Cooper CL, et al. Using technology to improve access to specialist care in amyotrophic lateral sclerosis: A systematic review. Amyotroph Lateral Scler Frontotemporal Degener.2016;17:313–24.
  13. Hollander JE, Carr BG. Virtually Perfect? Telemedicine for Covid-19. NEJM. 2020;382:1679–81.

Further Resources

Share this Article
Related Content In COVID-19
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72